ProCE Banner Activity

DSMM XIII: Phase III Trial of Rd Induction + ASCT With MEL140 Followed by R Maintenance vs Continuous Rd in Patients 60-75 Yr of Age With Newly Diagnosed MM

Slideset Download
Conference Coverage

Long-term follow-up did not show improved survival with lenalidomide/dexamethasone induction, reduced-intensity melphalan, and transplant followed by lenalidomide maintenance vs continuous lenalidomide/dexamethasone in patients 60-75 years of age with newly diagnosed multiple myeloma.

Released: December 12, 2022

Expiration: December 11, 2023

Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc

Novartis Pharmaceuticals Corporation

Sanofi

Seagen